Study 1 of 149 for search of: CAM USE AND CANCER
Previous Study Return to Search Results Next Study

Full Text View
Tabular View
No Study Results Posted
Related Studies
Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine
This study is currently recruiting participants.
Study NCT00608933   Information provided by National Cancer Institute (NCI)
First Received: January 30, 2008   Last Updated: February 6, 2009   History of Changes

January 30, 2008
February 6, 2009
June 2008
March 2011   (final data collection date for primary outcome measure)
Proportion of patients who report that the health provider discussed complimentary and alternative medicine (CAM) use [ Designated as safety issue: No ]
Proportion of patients who report that the nurse discussed complimentary and alternative medicine (CAM) use [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00608933 on ClinicalTrials.gov Archive Site
  • Frequency with which health providers ask about CAM use and referral for CAM use by health providers [ Designated as safety issue: No ]
  • Relationship between personal CAM use among health providers and frequency of asking patients about CAM use [ Designated as safety issue: No ]
  • Frequency and type of CAM use among patients diagnosed with cancer [ Designated as safety issue: No ]
  • Frequency with which nurses ask about CAM use and referral for CAM use by nurses [ Designated as safety issue: No ]
  • Relationship between personal CAM use among nurses and frequency of asking patients about CAM use [ Designated as safety issue: No ]
  • Frequency and type of CAM use among patients diagnosed with cancer [ Designated as safety issue: No ]
 
Education Intervention in Encouraging Health Providers to Talk With Cancer Patients About the Use of Complementary and Alternative Medicine
CAM USE and Cancer

RATIONALE: Educating health providers on talking with cancer patients about complementary and alternative medicine (CAM) may help encourage health providers to talk more often with cancer patients about the use of CAM.

PURPOSE: This randomized phase III trial is studying how well an education intervention works in encouraging health providers to talk with cancer patients about the use of CAM.

OBJECTIVES:

Primary

  • Examine the efficacy of an education intervention designed to increase the frequency with which health providers ask cancer patients about their use of complimentary and alternative medicine (CAM).

Secondary

  • Examine the frequency with which health providers ask about CAM use and referral for CAM use by health providers.
  • Evaluate whether personal CAM use among health providers is related to the frequency of asking patients about CAM use.
  • Assess the frequency and type of CAM use among patients diagnosed with cancer.

OUTLINE: This is a multicenter study. Stratification is based on the number of health providers at each CCOP component site (< 3 health providers per component site vs 3 to 6 health providers per component site vs 7 to 9 health providers per component site vs 10 or more health providers per component site). The CCOP component sites are randomized to 1 of 2 intervention groups.

  • Arm I (intervention): Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
  • Arm II (wait-list): Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I are made available to the wait-list health providers.

Health providers in both arms complete questionnaires at baseline and at 2 months to assess the effectiveness of the educational intervention, personal CAM use, and level of knowledge about CAM and to determine if they are asking patients about CAM use. Patients of the health providers also complete questionnaires at the same time points to assess personal CAM use before and after cancer diagnosis as well as the level of their interaction with health providers regarding CAM use.

Phase III
Interventional
Other, Randomized, Single Blind, Active Control
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Unspecified Childhood Solid Tumor, Protocol Specific
  • Other: educational intervention
  • Procedure: observation
  • Active Comparator: Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
  • No Intervention: Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I are made available to the wait-list health providers.
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
1360
 
March 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Health provider meeting the following criteria:

    • Has regular contact with cancer patients by initially talking with patients, taking their histories, and conveying pertinent information to their physician at a participating CCOP site

      • Must be actively seeing patients at a participating CCOP site
    • Must not be employed at more than one participating CCOP site
    • Not a temporary employee
  • Patient of a health provider at a participating CCOP site meeting the following criteria:

    • Current diagnosis of cancer including amyloidosis

      • Diagnosed at least 1 week ago
      • Finished treatment within the past 6 months
    • Able to speak or read English
    • No prior participation in this study at an earlier assessment

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
 
No
 
United States
 
NCT00608933
 
CDR0000584715, MDA-2006-0198
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Patricia A. Parker, PhD M.D. Anderson Cancer Center
National Cancer Institute (NCI)
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP